MedTrace Logo

SER100 in Isolated Systolic Hypertension

NCT01987284 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2016-10-20

No results posted yet for this study

Summary

Isolated Systolic Hypertension (ISH)is the dominating hypertensive disease in elderly people. Much attention has recently been drawn to the strong relationship between the systolic blood pressure and cardiovascular morbidity.

In previous clinical studies carried out in individuals with normal blood pressure at baseline SER100 decreased primarily the systolic blood pressure. It is hypothesized that the effect on systolic blood pressure in hypertensive patients will be larger or equal to the fall seen in normotensive patients.

Conditions

  • Isolated Systolic Hypertension

Interventions

DRUG

SER100

DRUG

Placebo

Sponsors & Collaborators

  • Smerud Medical Research International AS

    collaborator OTHER

  • The Research Council of Norway

    collaborator OTHER

  • Serodus AS

    lead INDUSTRY

Principal Investigators

  • Helga Gudmundsdottir, MD · Oslo University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-07-31
Completion
2014-09-30

Countries

  • Finland
  • Hungary
  • Norway
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01987284 on ClinicalTrials.gov